Overview

• U.S. biopharmaceutical firm's Q1 product revenue more than doubled, beating analyst expectations

• Net loss for Q1 widened yr/yr, reflecting higher R&D and SG&A expenses

• Company plans Q2 2026 sNDA submission for mitapivat in sickle cell disease

Outlook

• Company plans to submit mitapivat sNDA for sickle cell disease in Q2 2026

• Agios expects Phase 2b tebapivat LR-MDS topline results in first half 2026

• Company expects Phase 2 tebapivat sickle cell disease topline results in second half 2026

Result Drivers

• U.S. LAUNCH OF AQVESME - Q1 U.S. net revenue was driven by the commercial launch of AQVESME (mitapivat) in thalassemia in late January 2026

• EX-U.S. SALES - Ex-U.S. net revenue reflected demand for PYRUKYND (mitapivat) in thalassemia in Saudi Arabia

• HIGHER OPERATING EXPENSES - R&D and SG&A expenses rose due to pipeline advancement, workforce costs, and activities supporting AQVESME launch

Company press release: ID:nGNX4ySNK1

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q1 Product Revenue	Beat	$20.75 mln	$13.65 mln (10 Analysts)
Q1 Net Income		-$99.11 mln

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Agios Pharmaceuticals Inc is $41.00, about 65.3% above its April 28 closing price of $24.80

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.